- MCI Onehealth (DRDR) in collaboration with MDClone, announced an advanced clinical intelligence offering for their global partners
- The offering combines real-world health insights with mirrored synthetic data to power deeper research and inspire novel therapeutic development
- The collaboration with MDClone will accelerate MCI’s entry into the clinical insights and analytics sectors in the U.S. and Israel
- MCI is a healthcare technology company
- MCI Onehealth Technologies Inc. (DRDR) opened trading at C$1.26 per share
MCI Onehealth (DRDR), in collaboration with MDClone, announced an advanced clinical intelligence offering for their global partners.
The offering combines real-world health insights with mirrored synthetic data to power deeper research and inspire novel therapeutic development.
MCI’s tech-enabled network can capture real-world patient health journeys. It offers a comprehensive picture to researchers who can benefit from a fuller perspective. The partnership between MCI and MDClone will leverage MDClone’s technology to load, organize and protect MCI-generated patient data and use this data to help find insights to improve care.
MDClone offers clients robust, detailed data for thorough end-to-end, real-world analysis. Clinicians, researchers, and healthcare professionals can explore healthcare data more efficiently to accelerate real-world evidence processes, using MDClone ADAMS Platform analytics tools and synthetic data capabilities. Users can leverage self-service tools to access, analyze, and share information without privacy concerns. The real-time identification and extraction of information also allows users to overcome some of the common barriers that can slow clinical data projects’ progress.
Both companies also intend to work together to improve data collection and curation to better serve the needs of applied healthcare research.
MCI’s growing audience for health insights can further benefit from access to MDClone’s global roster of top-tier health systems and pharma relationships. The collaboration with MDClone will accelerate MCI’s entry into the clinical insights and analytics sectors in the U.S. and Israel. It also includes potential access to headquarters-level decision-makers of global pharma and life science leaders.
MCI is a healthcare technology company. It empowers patients and doctors with advanced technologies to increase access, improve quality, and reduce healthcare costs.
MCI Onehealth Technologies Inc. (DRDR) opened trading at C$1.26 per share.
